LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

Inicio・Lista de Acciones・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Cerrado

SectorSanidad

24.33 4.11

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

22.95

Máximo

24.34

Métricas clave
By Trading Economics
Ingresos	-2.8M -57M
Ventas	35K 730K
Margen de beneficios	-7,753.425
Empleados	186
EBITDA	-1.1M -63M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+129.03% upside

Dividendos
By Dow Jones
Próximas Ganancias	4 nov 2025

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	19M 1.5B
Apertura anterior	20.22
Cierre anterior	24.33

Noticias sobre sentimiento de mercado

By Acuity

100%

360 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

18.91 / 20.63 Soporte y Resistencia

Celldex Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

8 sept 2025, 23:59 UTC

Adquisiciones, fusiones, absorciones

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

8 sept 2025, 22:02 UTC

Principales Movimientos del Mercado

Microsoft Signs $17.4 Billion AI Deal With Nebius

8 sept 2025, 17:01 UTC

Principales Movimientos del Mercado

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

8 sept 2025, 17:01 UTC

Principales Movimientos del Mercado

Tron Shares Rise After New Investment From Bravemorning

8 sept 2025, 16:14 UTC

Principales Movimientos del Mercado

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

8 sept 2025, 16:13 UTC

Principales Movimientos del Mercado

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

8 sept 2025, 23:12 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

8 sept 2025, 23:12 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

8 sept 2025, 23:12 UTC

Charlas de Mercado

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

8 sept 2025, 22:56 UTC

Charlas de Mercado

Worst May Be Over for New Zealand Retailers -- Market Talk

8 sept 2025, 22:23 UTC

Charlas de Mercado

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

8 sept 2025, 21:51 UTC

Charlas de Mercado

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

8 sept 2025, 21:47 UTC

Principales Movimientos del Mercado

Microsoft Signs $17.4B AI Deal With Nebius

8 sept 2025, 21:33 UTC

Adquisiciones, fusiones, absorciones

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

8 sept 2025, 21:20 UTC

Adquisiciones, fusiones, absorciones

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

8 sept 2025, 21:19 UTC

Adquisiciones, fusiones, absorciones

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

8 sept 2025, 21:18 UTC

Adquisiciones, fusiones, absorciones

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

8 sept 2025, 20:50 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Tech, Media & Telecom Roundup: Market Talk

8 sept 2025, 19:33 UTC

Charlas de Mercado

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

8 sept 2025, 19:22 UTC

Charlas de Mercado

U.S. Natural Gas Futures Settle Higher -- Market Talk

8 sept 2025, 19:02 UTC

Charlas de Mercado

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

8 sept 2025, 18:24 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

8 sept 2025, 18:24 UTC

Charlas de Mercado

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

8 sept 2025, 17:29 UTC

Charlas de Mercado

Mexican Inflation Seen Little Changed in August -- Market Talk

8 sept 2025, 16:59 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

8 sept 2025, 16:36 UTC

Charlas de Mercado

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

8 sept 2025, 16:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

8 sept 2025, 16:16 UTC

Ganancias

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

8 sept 2025, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

8 sept 2025, 16:04 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Celldex Therapeutics Inc previsión

Precio Objetivo

By TipRanks

129.03% repunte

Estimación a 12 Meses

Media 52.38 USD 129.03%

Máximo 67 USD

Mínimo 38 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Celldex Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

10 ratings

Comprar

Mantener

Vender

De acuerdo con 10 analistas que ofrecen calificaciones bursátiles a para Celldex Therapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

18.91 / 20.63Soporte y Resistencia

Recent bullish events outweigh bearish events.

All events are bearish.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.